sm-346 and Mental-Disorders

To study afobasol efficacy in anxiety and neurotization correction in patients with celiac disease (CD).. We examined 17 CD patients with mental diseases (anxiety, anxiophobic and neurotic disorders) aged 35.3 +/- 3.5 years. Personal and situational anxiety levels were assessed with multivariate questionnaire of the integrative anxiety test, neurotization--with Wasserman's questionnaire. Mental diseases were treated for 4 weeks with afobasol in a daily dose 30 mg.. An initial level of personal anxiety was elevated in 100% patients, of situational anxiety--in 66.7%. These kinds of anxiety (most of all general, emotional discomfort, asthenic and phobic components) were treated with a positive effect. Neurotization was high in 11 patients. The treatment was effective in 6 of them. Side effects were not noted. The highest reduction was seen in emotional discomfort, asthenic component and anxiety.. Afobasol is effective in management of mental diseases in patients with celiac disease.

Topics: Adult; Anxiety Disorders; Benzimidazoles; Celiac Disease; Drug Administration Schedule; Female; Humans; Male; Mental Disorders; Morpholines; Phobic Disorders; Psychological Tests; Severity of Illness Index